Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
4.080
-0.470 (-10.33%)
At close: Mar 9, 2026, 4:00 PM EDT
4.050
-0.030 (-0.74%)
After-hours: Mar 9, 2026, 5:53 PM EDT
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K in the half year ending June 30, 2025, a decrease of -48.47%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm)
$560.00K
Revenue Growth
-16.04%
P/S Ratio
11.39
Revenue / Employee
$112,000
Employees
5
Market Cap
6.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Immuron | 4.99M |
| XTL Biopharmaceuticals | 968.00K |
| Aprea Therapeutics | 488.24K |
| Creative Medical Technology Holdings | 6.00K |
CANF News
- 5 days ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 5 days ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 5 days ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 5 days ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus
- 5 days ago - Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study - GlobeNewsWire
- 20 days ago - Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results - GuruFocus
- 4 weeks ago - Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson - GuruFocus
- 4 weeks ago - Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant - GuruFocus